Sai Life Sciences reports 109% increase in net profit for FY26

Arunika Jain — Thu, 14 May 2026 17:58:31 +0000

Sai Life Sciences Limited, a leading Contract Research, Development and Manufacturing Organisation (CRDMO) in India, has reported a significant financial upturn for the fiscal year ending 31 March 2026. The company’s net profit surged by 109% year-on-year, reaching ₹355 crore, compared to ₹170 crore in the previous fiscal year.

The company also achieved a 29% growth in revenue from operations, amounting to ₹2,192 crore for FY26, up from ₹1,695 crore in FY25. EBITDA for the year stood at ₹661 crore, marking a 56% increase from ₹425 crore in the prior year, with an EBITDA margin improvement from 25% to 30%.

Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences, highlighted the company’s strategic focus on deepening relationships with global pharmaceutical customers and expanding integrated CRDMO capabilities as key drivers of growth. “FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth,” he stated.

Siva Chittor, Chief Financial Officer, also emphasised the company’s strong execution across the business, supported by healthy growth in both revenues and EBITDA. “As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities,” he added.

The company’s growth has been attributed to deepening engagement with large pharma, momentum in integrated discovery services, and investments in new modalities and next-generation technologies. Sai Life Sciences incurred a capital expenditure of ₹633 crore during the fiscal year.

The company will conduct an earnings call on 15 May 2026 at 4:00 PM IST to discuss the financial and business performance of the quarter.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Siva Chittor | Business Upturn

Sai Life Sciences reports 109% increase in net profit for FY26